权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

MARKERS OF EXFOLIATED BENIGN AND MALIGNANT BLADDER CELLS

脱落的良性和恶性膀胱细胞的标记物

基本信息

批准号：
3191234
负责人：
CARLOS CORDON-CARDO
金额：
$ 13.24万
依托单位：
MEMORIAL HOSPITAL FOR CANCER & ALLIED DI
依托单位国家：
美国
项目类别：
财政年份：
1988
资助国家：
美国
起止时间：
1988-04-10 至 1992-03-31
项目状态：
已结题

项目摘要

Our overall objective is the evaluation of existing and newly developed monoclonal antibodies as potential tumor markers of exfoliated bladder epithelial cells, and to identify those markers of potential clinical value in detection of bladder tumors, predicting their behavior and response to therapy. The specific aims fall within three categories: 1) to rigorously test the sensitivity and specificity of binding to bladder tumor cells by a panel of 32 well characterized and presently available monoclonal antibodies to cell surface tumor-associated antigens, blood group related antigens, cytostructural antigens, oncogene- coded products, and growth factor receptors, (a) by immunohistochemistry on tissue sections of human bladder tumors, reactive or metaplastic urothelium in inflammatory processes and normal urothelium, (b) by immunocytochemistry on cytology smears of exfoliated bladder epithelial cells from patients with bladder tumors, cystitis and normal mucosa, (c) flow cytometry of bladder irrigation specimens and cell suspensions from resected tumors using dual parameter DNA/monoclonal antibody binding measurements and three parameter-dual laser DNA/double monoclonal antibody binding, 2) to correlate the antigenic phenotype of bladder tumors analyzed with (a) conventional histopathologic and cytologic features and flow cytometry parameters, (b) clinical course including tumor progression, metastases, and response to therapy, and 3) to establish a new subclassification of human bladder tumors based on immunophenotypic features reliable and useful in clinical management and prognosis. Our evaluation will involve comparative analysis of the cytology of exfoliated bladder epithelial cells, histology of resected tumors, flow cytometry of cell suspensions and bladder irrigation specimens, cystoscopy and biopsy findings; and a sequential evaluation of all the parameters mentioned above during follow- up of patients treated conservatively. These multiparameter analyses of human bladder tumors are expected to yield new markers for immunodiagnosis and important information about cellular differentiation and transformation.

我们的总体目标是评估现有的和新的开发的单克隆抗体作为潜在的肿瘤标志物，脱落的膀胱上皮细胞，并确定这些标志物在检测膀胱肿瘤方面具有潜在的临床价值，预测他们的行为和对治疗的反应具体目标分为三类：1）严格检测与膀胱肿瘤结合的敏感性和特异性通过一组32个已充分表征且目前可用的细胞，细胞表面肿瘤相关抗原的单克隆抗体，血型相关抗原，细胞结构抗原，癌基因- 编码产物和生长因子受体，（a）通过人膀胱组织切片免疫组织化学研究肿瘤、反应性或化生性尿路上皮炎（B）通过免疫细胞化学检测，脱落的膀胱上皮细胞的细胞学涂片，患有膀胱肿瘤、膀胱炎和正常粘膜的患者，（c）流动膀胱冲洗标本和细胞悬液的细胞计数使用双参数DNA/单克隆抗体结合测量和三参数双激光 DNA/双单克隆抗体结合，2）将用（a）分析的膀胱肿瘤的抗原表型常规组织病理学和细胞学特征和血流细胞计数参数，（B）临床过程，包括肿瘤进展、转移和对治疗的反应，以及3）建立一个新的人类膀胱肿瘤亚分类，免疫表型特征的可靠性和临床实用性管理和预后。我们的评估将包括细胞学的比较分析脱落的膀胱上皮细胞，切除的组织学肿瘤、细胞悬液流式细胞术和膀胱冲洗标本、膀胱镜检查和活检结果;以及在以下期间评估上述所有参数- 保守治疗的患者占60%。这些多参数对人类膀胱肿瘤的分析有望产生新的用于免疫诊断的标记物和关于细胞分化和转化。